By IPOMarket Editorial Team · Last reviewed: May 20, 2026
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
The Q-Line Biotech IPO 2026 is one of the largest NSE SME issues ever attempted — opening on May 21, 2026 and closing May 25, 2026 at a price band of ₹326-343 per share for a total raise of ₹214.48 crore through a 100% fresh issue. The Lucknow-based In-Vitro Diagnostics (IVD) company brings to market diagnostic reagents, IVD kits, pathology equipment and rapid test kits — a healthcare segment with strong structural tailwinds from India's expanding diagnostics infrastructure.
This review covers the IPO mechanics, business model, financial scale (including the FY25 PAT decline that investors must understand), pre-IPO investor base, and a decision framework for prospective applicants. For broader pipeline context, see our open IPOs page and the live IPO GMP page.
Q-Line Biotech IPO — Key Details at a Glance
| Parameter | Details |
|---|---|
| Open Date | May 21, 2026 |
| Close Date | May 25, 2026 |
| Allotment Date | May 26, 2026 |
| Listing Date | May 29, 2026 |
| Price Band | ₹326 – ₹343 per share |
| Issue Size | ₹214.48 Cr (100% Fresh Issue) |
| Lot Size | 400 shares |
| Min Investment (Retail) | ₹2,74,400 (800 shares) |
| Exchange | NSE SME Emerge |
| Lead Manager | Hem Securities + Share India Capital Services |
| Registrar | Purva Sharegistry |
| GMP Today | Live IPO GMP → |
| Allotment Status | Check allotment → |
About Q-Line Biotech
Q-Line Biotech is a Lucknow-based In-Vitro Diagnostics (IVD) company founded in 2013. The company manufactures and supplies a comprehensive range of diagnostic products including:
- Diagnostic reagents. Chemistry reagents for biochemical analyzers — a recurring-revenue consumable category.
- IVD kits. Multi-component kits for biochemistry, immunoassays and specialty diagnostics.
- Pathology equipment. Selectra biochemistry analyzers and pathology lab equipment.
- Rapid test kits. Point-of-care diagnostic kits for infectious disease and other indications.
The company's annual capacity is 1.4 million diagnostic kits and 1,200 Selectra machines — meaningful scale for a domestic IVD manufacturer.
The Indian IVD market is in a multi-year expansion phase driven by:
- Diagnostic chain explosion. Pan-India chains (Dr Lal, Metropolis, Thyrocare, SRL and others) are expanding aggressively into Tier-2/3 cities.
- Government health programmes. Ayushman Bharat and state-level diagnostic schemes drive equipment and reagent demand.
- Make in India / Atmanirbhar diagnostics. Policy preference for domestic IVD manufacturing over imports.
Financial Performance — Strong Topline, PAT Decline to Watch
| Metric | FY24 | FY25 | Movement |
|---|---|---|---|
| Revenue | ₹206.45 Cr | ₹322.58 Cr | +56% |
| PAT | ₹34.44 Cr | ₹28.13 Cr | -18% |
Two important observations:
- Topline grew 56% — strong demand-side performance reflecting product portfolio expansion and customer base growth.
- PAT declined 18% despite revenue growth — this is the single most important data point in the prospectus. Possible drivers include input cost pressure, increased competitive intensity, expansion-related opex, or one-time items. Investors must read the RHP carefully to understand the margin compression.
The pre-IPO valuation context: Q-Line raised ₹27.44 crore in a pre-IPO round at ₹343 per share (the upper band of the IPO) in May 2026, with notable investor Vikas Vijaykumar Khemani (Carnelian Asset Management founder) investing ₹14.94 crore. The fact that pre-IPO investors entered at the same ₹343 price as the IPO upper band — rather than at the typical 15-25% pre-IPO discount — indicates strong institutional conviction in the FY26+ trajectory.
GMP and Market Sentiment
Live GMP data for the Q-Line Biotech IPO should be tracked on the GMP page — at this scale (₹214 Cr) the issue will attract meaningful HNI and institutional grey-market activity. Investors should also monitor subscription momentum on the live SME subscription page.
Use of IPO Proceeds
The ₹214.48 crore fresh issue proceeds will be deployed across:
- ₹93.5 Cr — Working capital. Funding the receivables cycle for diagnostic chain and B2B clients.
- ₹90 Cr — Debt repayment. Materially reducing the interest cost burden — a positive for FY27 net margin.
- Balance — General corporate purposes and issue expenses.
The ₹90 crore debt repayment is significant — interest cost reduction will be a direct margin tailwind, partially offsetting the FY25 PAT compression observed.
Strengths
- Healthcare sector tailwind. Indian IVD market structural growth from diagnostic chain expansion and government health programmes.
- Strong topline growth. 56% revenue growth in FY25 demonstrates demand traction.
- Manufacturing scale. 1.4 million kits and 1,200 Selectra machines per year is meaningful capacity for a domestic IVD player.
- Strong pre-IPO investor anchor. Vikas Khemani's ₹14.94 Cr investment at IPO price reflects institutional conviction.
- Debt repayment from proceeds. ₹90 Cr debt repayment will materially improve net margin trajectory.
- Atmanirbhar tailwind. Policy preference for domestic IVD manufacturing.
Risks and Concerns
- FY25 PAT decline. The 18% PAT drop despite 56% revenue growth must be understood from the RHP — this is the single most important risk factor.
- High debt. The ₹90 Cr debt repayment indicates the company has been operating with material leverage — execution risk if revenue growth slows.
- SME platform listing. Despite the ₹214 Cr scale, the listing is on NSE SME Emerge, not mainboard — lower daily liquidity in the early years.
- Competitive intensity. Indian IVD has both global players (Roche, Abbott, Siemens) and aggressive domestic competitors (Transasia, Tulip, Mylab).
- Working capital intensity. Diagnostic chain receivables can stretch 60-90+ days.
Should You Apply?
The decision framework for Q-Line rests on three balancing factors:
- For. Strong topline growth, healthcare sector tailwind, pre-IPO anchor at IPO price, debt repayment from proceeds, and manufacturing scale.
- Against. FY25 PAT decline despite revenue growth, high debt, and SME listing liquidity caveats.
- Neutral. Competitive intensity is structural to the IVD category — not unique to Q-Line.
For investors with appetite for SME healthcare exposure and conviction on Indian IVD expansion, the underlying scale and pre-IPO investor signal supports a measured application. The PAT decline is the single most important due diligence item — applicants should read the RHP carefully and understand the drivers. Track subscription momentum on the live SME subscription page before committing. For the company's full IPO profile, see Q-Line Biotech.
Key Dates
| Event | Date |
|---|---|
| Open Date | May 21, 2026 |
| Close Date | May 25, 2026 |
| Allotment Finalization | May 26, 2026 |
| Refunds Initiated | May 27, 2026 |
| Shares Credited to Demat | May 28, 2026 |
| Listing Date | May 29, 2026 |
Frequently Asked Questions
What is the Q-Line Biotech IPO price band? The price band is ₹326 to ₹343 per share with a lot size of 400 shares. The minimum retail investment is ₹2,74,400 (800 shares).
When is the Q-Line Biotech IPO listing date? The shares are expected to list on NSE SME Emerge on May 29, 2026 following allotment on May 26, 2026.
What is the Q-Line Biotech IPO size? The issue size is ₹214.48 crore (100% fresh issue) — one of the largest NSE SME IPOs to date.
What is the Q-Line Biotech IPO GMP today? Check the live IPO GMP page for the latest GMP — Q-Line is the highest-profile SME IPO of May 2026 and will attract meaningful grey-market activity.
Who is the notable pre-IPO investor in Q-Line? Vikas Vijaykumar Khemani (founder of Carnelian Asset Management) invested ₹14.94 crore at the ₹343 IPO upper-band price in May 2026.
Why did Q-Line's PAT decline in FY25? PAT declined from ₹34.44 Cr (FY24) to ₹28.13 Cr (FY25) despite revenue growth of 56%. Drivers will be detailed in the RHP — likely a combination of input cost pressure, opex from expansion, and interest cost. The ₹90 Cr debt repayment from IPO proceeds is designed to reverse the interest cost component.
How can I check Q-Line Biotech IPO allotment status? Use our IPO allotment status checker or the registrar (Purva Sharegistry) portal. PAN-based lookup gives instant status.
This article is for informational purposes only and does not constitute investment advice. Please read the RHP carefully before investing.